U.S. Markets open in 6 hrs 56 mins

Repligen Corporation (RGEN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
43.76-0.39 (-0.88%)
At close: 4:00PM EDT
People also watch
SCLNNBIXSGMOPGNXLGND

Repligen Corporation

Building 1
Suite 100
Waltham, MA 02453
United States
781-250-0111
http://www.repligen.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees236

Key Executives

NameTitlePayExercisedAge
Mr. Anthony J. HuntChief Exec. Officer, Pres, Director and Member of Scientific Advisory Board903.25kN/A53
Mr. Jon K. SnodgresChief Financial Officer and Sec.523.35kN/A51
Dr. Howard Benjamin Ph.D.VP of Bus. Devel.411.99k177.49k57
Mr. Steve CurranVP of Global OperationsN/AN/AN/A
Ms. Sondra S. NewmanSr. Director Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Repligen Corporation, a bioprocessing company, focuses on the development, production, and commercialization of products used in the production of antibody-based therapeutics, recombinant proteins, and vaccines worldwide. It manufactures various forms of Protein A, a critical component used to purify antibody-based drugs. The company also supplies alternating tangential flow system filtration devices and protein cell culture supplements that are used in clinical and commercial stage manufacturing to enhance biologic drug yields. In addition, it manufactures and sells OPUS pre-packed chromatography columns, which are used in the purification of clinical-stage biologics; and tangential flow filtration cassettes that are used to concentrate clinical and commercial stage biologic drugs. Further, the company has a portfolio of therapeutic product candidates, which include histone deacetylase inhibitor for the treatment of Friedreich’s ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other pancreatic diseases. The company sells its bioprocessing products directly and through distributors to various life sciences companies, biopharmaceutical companies, and contract manufacturers. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Repligen Corporation’s ISS Governance QualityScore as of September 1, 2017 is 1. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.